Demethoxycurcumin increases the sensitivity of cisplatin‑resistant non‑small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway

Chen,Yun; Hong,Chaojin; Chen,Xiaochen; Qin,Zhiquan

doi:10.3892/ol.2020.12072

Demethoxycurcumin increases the sensitivity of cisplatin‑resistant non‑small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway

Authors:
- Yun Chen
- Chaojin Hong
- Xiaochen Chen
- Zhiquan Qin
View Affiliations

Affiliations: Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
Published online on: September 8, 2020 https://doi.org/10.3892/ol.2020.12072
Article Number: 209
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with non‑small cell lung cancer (NSCLC) can develop strong drug resistance following long‑term treatment with platinum‑based drugs. Increasing doses of chemotherapeutic drugs fail to obtain better results, and serious complications occur. It has been demonstrated that upregulation of excision repair cross‑complementary 1 (ERCC1) in lung cancer cells is closely associated with cell resistance to platinum‑based chemotherapy. In addition, curcumin (CMN) enhances antitumor effects in NSCLC by downregulating ERCC1. The aim of the present study was to investigate the effects of demethoxycurcumin (DMC), a curcuminoid, on the reversal of resistance of NSCLC cells in vitro and in vivo. The present study demonstrated that DMC significantly increased the sensitivity of DDP in DDP‑resistant A549 (A549/DDP) cells. The results from an MTT assay demonstrated that DMC combined with DDP significantly attenuated the proliferation of A549/DDP cells. Furthermore, DMC exhibited decreased toxicity in normal lung fibroblast MRC‑5 cells. In addition, following treatment of A549/DDP cells with a combination of DMC and DDP, the expression of ERCC1 was reduced, the protein levels of Bcl‑2 and Bax were decreased and increased, respectively, whereas caspase‑3 was activated, according to results from western blotting. Finally, DDP combined with DMC significantly attenuated A549/DDP cell‑derived tumor growth in vivo. Taken together, the findings from the present study suggested that DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP‑resistant NSCLC cells.

View Figures

View References

1	Nasim F, Sabath BF and Eapen GA: Lung cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
2	Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017. View Article : Google Scholar : PubMed/NCBI
3	Rinaldi M, Cauchi C and Gridelli C: First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol. 17 (Suppl 5):v64S–v67S. 2006. View Article : Google Scholar
4	Ke B, Wei T, Huang Y, Gong Y, Wu G, Liu J, Chen X and Shi L: Interleukin-7 resensitizes non-small-cell lung cancer to cisplatin via inhibition of ABCG2. Mediators Inflamm. 2019:72414182019. View Article : Google Scholar : PubMed/NCBI
5	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
6	Amable L: Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 106:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
7	Janyou A, Changtam C, Suksamrarn A, Tocharus C and Tocharus J: Suppression effects of O-demethyldemethoxycurcumin on thapsigargin triggered on endoplasmic reticulum stress in SK-N-SH cells. Neurotoxicology. 50:92–100. 2015. View Article : Google Scholar : PubMed/NCBI
8	Simental-Mendia LE, Pirro M, Gotto AM Jr, Banach M, Atkin SL, Majeed M and Sahebkar A: Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 59:1178–1187. 2019. View Article : Google Scholar : PubMed/NCBI
9	Benediktsdottir BE, Baldursson O, Gudjonsson T, Tonnesen HH and Masson M: Curcumin, bisdemethoxycurcumin and dimethoxycurcumin complexed with cyclodextrins have structure specific effect on the paracellular integrity of lung epithelia in vitro. Biochem Biophys Rep. 4:405–410. 2015.PubMed/NCBI
10	Yuan F, Dong H, Gong J, Wang D, Hu M, Huang W, Fang K, Qin X, Qiu X, Yang X and Lu F: A systematic review and meta-analysis of randomized controlled trials on the effects of turmeric and curcuminoids on blood lipids in adults with metabolic diseases. Adv Nutr. 10:791–802. 2019. View Article : Google Scholar : PubMed/NCBI
11	Imran M, Ullah A, Saeed F, Nadeem M, Arshad MU and Suleria HAR: Cucurmin, anticancer, & antitumor perspectives: A comprehensive review. Crit Rev Food Sci Nutr. 58:1271–1293. 2018. View Article : Google Scholar : PubMed/NCBI
12	Al Ayoub Y, Gopalan RC, Najafzadeh M, Mohammad MA, Anderson D, Paradkar A and Assi KH: Development and evaluation of nanoemulsion and microsuspension formulations of curcuminoids for lung delivery with a novel approach to understanding the aerosol performance of nanoparticles. Int J Pharm. 557:254–263. 2019. View Article : Google Scholar : PubMed/NCBI
13	Adiwidjaja J, McLachlan AJ and Boddy AV: Curcumin as a clinically-promising anti-cancer agent: Pharmacokinetics and drug interactions. Expert Opin Drug Metab Toxicol. 13:953–972. 2017. View Article : Google Scholar : PubMed/NCBI
14	Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Tan BK, Kumar AP and Sethi G: The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 20:2728–2769. 2015. View Article : Google Scholar : PubMed/NCBI
15	Hassanalilou T, Ghavamzadeh S and Khalili L: Curcumin and gastric cancer: A review on mechanisms of action. J Gastrointest Cancer. 50:185–192. 2019. View Article : Google Scholar : PubMed/NCBI
16	Mendonca LM, Machado Cda S, Teixeira CC, Freitas LA, Bianchi ML and Antunes LM: Comparative study of curcumin and curcumin formulated in a solid dispersion: Evaluation of their antigenotoxic effects. Genet Mol Biol. 38:490–498. 2015. View Article : Google Scholar : PubMed/NCBI
17	Quitschke WW: Differential solubility of curcuminoids in serum and albumin solutions: Implications for analytical and therapeutic applications. BMC Biotechnol. 8:842008. View Article : Google Scholar : PubMed/NCBI
18	Chen G, Chen Y, Yang N, Zhu X, Sun L and Li G: Interaction between curcumin and mimetic biomembrane. Sci China Life Sci. 55:527–532. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hatamipour M, Ramezani M, Tabassi SAS, Johnston TP and Sahebkar A: Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseases. J Cell Physiol. 234:19320–19330. 2019. View Article : Google Scholar : PubMed/NCBI
20	Lee JW, Hong HM, Kwon DD, Pae HO and Jeong HJ: Dimethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean J Urol. 51:870–878. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ni X, Zhang A, Zhao Z, Shen Y and Wang S: Demethoxycurcumin inhibits cell proliferation, migration and invasion in prostate cancer cells. Oncol Rep. 28:85–90. 2012.PubMed/NCBI
22	Ko YC, Lien JC, Liu HC, Hsu SC, Lin HY, Chueh FS, Ji BC, Yang MD, Hsu WH and Chung JG: Demethoxycurcumin-induced DNA damage decreases DNA Repair-associated protein expression levels in NCI-H460 human lung cancer cells. Anticancer Res. 35:2691–2698. 2015.PubMed/NCBI
23	Ko YC, Lien JC, Liu HC, Hsu SC, Ji BC, Yang MD, Hsu WH and Chung JG: Demethoxycurcumin induces the apoptosis of human lung cancer NCI-H460 cells through the mitochondrial-dependent pathway. Oncol Rep. 33:2429–2437. 2015. View Article : Google Scholar : PubMed/NCBI
24	Chang HB and Chen BH: Inhibition of lung cancer cells A549 and H460 by curcuminoid extracts and nanoemulsions prepared from Curcuma longa linnaeus. Int J Nanomedicine. 10:5059–5080. 2015.PubMed/NCBI
25	McNeil EM and Melton DW: DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 40:9990–10004. 2012. View Article : Google Scholar : PubMed/NCBI
26	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
27	Ashkenazi A, Fairbrother WJ, Leverson JD and Souers AJ: From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 16:273–284. 2017. View Article : Google Scholar : PubMed/NCBI
28	Rheaume E, Cohen LY, Uhlmann F, Lazure C, Alam A, Hurwitz J, Sékaly RP and Denis F: The large subunit of replication factor C is a substrate for caspase-3 in vitro and is cleaved by a caspase-3-like protease during Fas-mediated apoptosis. EMBO J. 16:6346–6354. 1997. View Article : Google Scholar : PubMed/NCBI
29	Rotolo F, Dunant A, Le Chevalier T, Pignon JP and Arriagada R; IALT Collaborative Group, : Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: New insights into the effect on failure type via a multistate approach. Ann Oncol. 25:2162–2166. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C and Franco Conte P: A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Cancer. 89:1714–1719. 2000. View Article : Google Scholar : PubMed/NCBI
31	Moldvay J, Rokszin G, Abonyi-Toth Z, Katona L and Kovacs G: Analysis of drug therapy of lung cancer in Hungary. Magy Onkol. 57:33–38. 2013.(In Hungarian). PubMed/NCBI
32	Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B and Yeger H: Combination therapy in combating cancer. Oncotarget. 8:38022–38043. 2017. View Article : Google Scholar : PubMed/NCBI
33	Hung CM, Su YH, Lin HY, Lin JN, Liu LC, Ho CT and Way TD: Demethoxycurcumin modulates prostate cancer cell proliferation via AMPK-induced down-regulation of HSP70 and EGFR. J Agric Food Chem. 60:8427–8434. 2012. View Article : Google Scholar : PubMed/NCBI
34	Sheu MJ, Lin HY, Yang YH, Chou CJ, Chien YC, Wu TS and Wu CH: Demethoxycurcumin, a major active curcuminoid from Curcuma longa, suppresses balloon injury induced vascular smooth muscle cell migration and neointima formation: An in vitro and in vivo study. Mol Nutr Food Res. 57:1586–1597. 2013. View Article : Google Scholar : PubMed/NCBI
35	Teng YN, Hsieh YW, Hung CC and Lin HY: Demethoxycurcumin modulates human P-glycoprotein function via uncompetitive inhibition of ATPase hydrolysis activity. J Agric Food Chem. 63:847–855. 2015. View Article : Google Scholar : PubMed/NCBI
36	Ruiz de Porras V, Bystrup S, Martinez-Cardus A, Pluvinet R, Sumoy L, Howells L, James MI, Iwuji C, Manzano JL, Layos L, et al: Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-KB signalling pathway. Sci Rep. 6:246752016. View Article : Google Scholar : PubMed/NCBI
37	Zhao S, Pi C, Ye Y, Zhao L and Wei Y: Recent advances of analogues of curcumin for treatment of cancer. Eur J Med Chem. 180:524–535. 2019. View Article : Google Scholar : PubMed/NCBI
38	Changtam C, Hongmanee P and Suksamrarn A: Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur J Med Chem. 45:4446–4457. 2010. View Article : Google Scholar : PubMed/NCBI
39	Chen YY, Lin YJ, Huang WT, Hung CC, Lin HY, Tu YC, Liu DM, Lan SJ and Sheu MJ: Demethoxycurcumin-Loaded chitosan nanoparticle downregulates DNA repair pathway to improve cisplatin-induced apoptosis in non-small cell lung cancer. Molecules. 23:32172018. View Article : Google Scholar
40	Zhu H, Luo H, Zhang W, Shen Z, Hu X and Zhu X: Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 10:1885–1895. 2016. View Article : Google Scholar : PubMed/NCBI
41	Vikhanskaya F, Marchini S, Marabese M, Galliera E and Broggini M: P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res. 61:935–938. 2001.PubMed/NCBI
42	Tsai MS, Weng SH, Kuo YH, Chiu YF and Lin YW: Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Mol Pharmacol. 80:136–146. 2011. View Article : Google Scholar : PubMed/NCBI
43	Lin CY, Hung CC, Wang CCN, Lin HY, Huang SH and Sheu MJ: Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways. Phytomedicine. 53:28–36. 2019. View Article : Google Scholar : PubMed/NCBI